Impact of Neutrophil Lymphocyte and Monocyte Lymphocyte Ratio on Chronic Kidney Disease Patients Outcome
1 other identifier
observational
200
0 countries
N/A
Brief Summary
The aim of this study is to establish NLR, MLR as a good predictors for outcome of CKD including hemodialysis and CKD stage (4-5) patients as regard inflammation, malnutrition and anemia on cardiovascular complication.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2023
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 25, 2023
CompletedStudy Start
First participant enrolled
June 1, 2023
CompletedFirst Posted
Study publicly available on registry
June 5, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2024
CompletedJune 5, 2023
May 1, 2023
1.1 years
April 25, 2023
May 24, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Impact of neutrophil lymphocyte and monocyte lymphocyte ratio on chronic kidney disease patients outcome
Neutrophil to lymphocyte ratio and monocyte to lymphocyte ratio in addition to subtypes of monocytes will be measured in healthy persons, CKD patients stage (4-5) and in chronic hemodialysis patients and use it as inflamamtory markers as well as it's a good predictors for cardiovascular complications and what's the impact of it's ratio degree on CKD patients outcome
baseline
Study Arms (3)
1
healthy persons to see normal ratio of of neutrophil lymphocyte and monocyte lymphocyte
2
CKD patients stage (4-5) not on dialysis to see impact of (NLR) and (MLR) as regard inflamation and cardiovascular complications
3
patients ESRD on maintenance hemodialysis compared with CKD pre dialysis patents and see if hemodialysis is better for removal toxic granules and inflamatory markers caused by CKD
Interventions
all groups assigned Cbc with leukocyte differential and flow cytometry for monocyte population
Eligibility Criteria
healthy persons as control group patients with chronic kidney disease (CKD) stage 4-5 (not on dialysis) patients ESRD on maintenance hemodialysis
You may qualify if:
- \- Hemodialysis patients \> 18 years
- \< 60 years old
- CKD stage (4-5) not on dialysis
You may not qualify if:
- o Recent acute coronary or cerebrovascular accident
- Autoimmune diseases
- Hematological diseases
- Liver cirrhosis
- Active or pre-active infection
- Malignancy
- Medications as Aspirin, NSAI, immunosuppressive steroid.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (9)
Kim JK, Hong CW, Park MJ, Song YR, Kim HJ, Kim SG. Increased Neutrophil Extracellular Trap Formation in Uremia Is Associated with Chronic Inflammation and Prevalent Coronary Artery Disease. J Immunol Res. 2017;2017:8415179. doi: 10.1155/2017/8415179. Epub 2017 Mar 27.
PMID: 28523279BACKGROUNDGirndt M, Trojanowicz B, Ulrich C. Monocytes in Uremia. Toxins (Basel). 2020 May 21;12(5):340. doi: 10.3390/toxins12050340.
PMID: 32455723BACKGROUNDRamirez R, Carracedo J, Merino A, Soriano S, Ojeda R, Alvarez-Lara MA, Martin-Malo A, Aljama P. CD14+CD16+ monocytes from chronic kidney disease patients exhibit increased adhesion ability to endothelial cells. Contrib Nephrol. 2011;171:57-61. doi: 10.1159/000327134. Epub 2011 May 23.
PMID: 21625090RESULTChapter 1: Definition and classification of CKD. Kidney Int Suppl (2011). 2013 Jan;3(1):19-62. doi: 10.1038/kisup.2012.64. No abstract available.
PMID: 25018975RESULTKato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1526-33. doi: 10.2215/CJN.00950208. Epub 2008 Aug 13.
PMID: 18701615RESULTSarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 2000 Oct;58(4):1758-64. doi: 10.1111/j.1523-1755.2000.00337.x.
PMID: 11012910RESULTMansur A, Mulwande E, Steinau M, Bergmann I, Popov AF, Ghadimi M, Beissbarth T, Bauer M, Hinz J. Chronic kidney disease is associated with a higher 90-day mortality than other chronic medical conditions in patients with sepsis. Sci Rep. 2015 May 21;5:10539. doi: 10.1038/srep10539.
PMID: 25995131RESULTJames MT, Laupland KB, Tonelli M, Manns BJ, Culleton BF, Hemmelgarn BR; Alberta Kidney Disease Network. Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. Arch Intern Med. 2008 Nov 24;168(21):2333-9. doi: 10.1001/archinte.168.21.2333.
PMID: 19029498RESULTHaag-Weber M, Horl WH. Dysfunction of polymorphonuclear leukocytes in uremia. Semin Nephrol. 1996 May;16(3):192-201.
PMID: 8734462RESULT
Related Links
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ashraf AN el shazly, profeassor
Assiut University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 12 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Impact of neutrophil lymphocyte and monocyte lymphocyte ratio on chronic kidney disease patients outcome
Study Record Dates
First Submitted
April 25, 2023
First Posted
June 5, 2023
Study Start
June 1, 2023
Primary Completion
July 1, 2024
Study Completion
October 1, 2024
Last Updated
June 5, 2023
Record last verified: 2023-05